Staphylococcus saprophyticus: Difference between revisions
No edit summary |
|||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 12: | Line 12: | ||
| binomial_authority = (Fairbrother 1940)<br>Shaw ''et al.'' 1951 | | binomial_authority = (Fairbrother 1940)<br>Shaw ''et al.'' 1951 | ||
}} | }} | ||
__NOTOC__ | |||
{{CMG}} | |||
==Overview== | |||
'''''Staphylococcus saprophyticus''''' is a [[coagulase]]-negative species of ''[[Staphylococcus]]'' bacteria (which are [[catalase]]-positive). ''S. saprophyticus'' is often implicated in [[urinary tract infection]]s. ''S. saprophyticus'' is '''resistant''' to the antibiotic [[Novobiocin]], a characteristic that is used in laboratory identification to distinguish it from ''S. epidermitis'', which is also coagulase- negative. | '''''Staphylococcus saprophyticus''''' is a [[coagulase]]-negative species of ''[[Staphylococcus]]'' bacteria (which are [[catalase]]-positive). ''S. saprophyticus'' is often implicated in [[urinary tract infection]]s. ''S. saprophyticus'' is '''resistant''' to the antibiotic [[Novobiocin]], a characteristic that is used in laboratory identification to distinguish it from ''S. epidermitis'', which is also coagulase- negative. | ||
| Line 22: | Line 26: | ||
[[Quinolones]] are commonly used in treatment of ''S. saprophyticus'' urinary tract infections. | [[Quinolones]] are commonly used in treatment of ''S. saprophyticus'' urinary tract infections. | ||
==Treatment== | |||
===Antimicrobial Regimen=== | |||
:* '''Urinary tract infections'''<ref>{{cite book | last = Abramowicz | first = Mark | title = Handbook of antimicrobial therapy : selected articles from Treatment guidelines with updates from The medical letter | publisher = The Medical Letter | location = New Rochelle, N.Y | year = 2011 | isbn = 978-0981527826 }}</ref> | |||
::* Preferred regimen (1): [[Cephalexin]] 500 mg PO qid | |||
::* Preferred regimen (2): [[Amoxicillin-Clavulanate]] 875/125 mg PO bid | |||
::* Preferred regimen (3): [[TMP-SMX]] 160–800 mg PO bid | |||
::* Alternative regimen: [[Levofloxacin]] 500 mg PO qd | |||
==References== | |||
{{reflist|2}} | |||
[[Category:Gram positive bacteria]] | [[Category:Gram positive bacteria]] | ||
[[Category:Staphylococcaceae]] | [[Category:Staphylococcaceae]] | ||
Latest revision as of 14:14, 12 August 2015
| Staphylococcus saprophyticus | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scientific classification | ||||||||||||||
| ||||||||||||||
| Binomial name | ||||||||||||||
| Staphylococcus saprophyticus (Fairbrother 1940) Shaw et al. 1951 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Staphylococcus saprophyticus is a coagulase-negative species of Staphylococcus bacteria (which are catalase-positive). S. saprophyticus is often implicated in urinary tract infections. S. saprophyticus is resistant to the antibiotic Novobiocin, a characteristic that is used in laboratory identification to distinguish it from S. epidermitis, which is also coagulase- negative.
The organism is rarely found in healthy humans but is commonly isolated from animals and their carcasses.
It is implicated in 10-20% of urinary tract infections (UTI). In females between the ages of ca. 17-27 it is the second most common cause of UTIs. It may also reside in the urinary tract and bladder of sexually active females. S. saprophyticus is phosphatase-negative, urease and lipase positive.
Some of the symptoms of this bacteria are burning sensation when passing urine, the urge to go to the toilet more often than usual, the 'dripping effect' after urination, weak bladder, bloated feeling with sharp razor pains in the lower abdomen around the bladder and ovary areas and razor-like pains during sexual intercourse.
Quinolones are commonly used in treatment of S. saprophyticus urinary tract infections.
Treatment
Antimicrobial Regimen
- Urinary tract infections[1]
- Preferred regimen (1): Cephalexin 500 mg PO qid
- Preferred regimen (2): Amoxicillin-Clavulanate 875/125 mg PO bid
- Preferred regimen (3): TMP-SMX 160–800 mg PO bid
- Alternative regimen: Levofloxacin 500 mg PO qd
References
- ↑ Abramowicz, Mark (2011). Handbook of antimicrobial therapy : selected articles from Treatment guidelines with updates from The medical letter. New Rochelle, N.Y: The Medical Letter. ISBN 978-0981527826.